Article info
PDFHow to do it
Azathioprine and the neurologist
- Correspondence to Dr Usman Khan, Neurology, St George's University Hospital, London SW17 0QT, UK; usman.khan4{at}nhs.net
Citation
Azathioprine and the neurologist
Publication history
- Accepted July 8, 2019
- First published August 23, 2019.
Online issue publication
July 02, 2020
Article Versions
- Previous version (14 January 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- TPMT testing before azathioprine therapy?
- Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease
- A practical guide to thiopurine prescribing and monitoring in IBD
- Optimising use of thiopurines in inflammatory bowel disease
- Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease
- TPMT in the treatment of Crohn's disease with azathioprine
- Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease
- Azathioprine-induced pancytopenia with normal TPMT activity presenting with HSV oral ulcers
- Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come
- Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease